(Q47782406)

English

Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.

scientific article published on 13 August 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23943608

Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. (English)

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23943608

Charlotte F. McDonagh

8

object named as

Charlotte F McDonagh

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23943608

author name string

Daniel C Kirouac

1

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23943608

Jin Y Du

2

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23943608

Johanna Lahdenranta

3

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23943608

Ryan Overland

4

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23943608

Defne Yarar

5

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23943608

Violette Paragas

6

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23943608

Emily Pace

7

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23943608

Ulrik B Nielsen

9

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23943608

Matthew D Onsum

10

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23943608

publication date

13 August 2013

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23943608

Science Signaling

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23943608

6

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23943608

288

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23943608

ra68

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23943608

Protein molecules as computational elements in living cells

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Towards genome-scale signalling network reconstructions

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Oncogenic kinase signalling

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Navigating cancer network attractors for tumor-specific therapy

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

The landscape of somatic copy-number alteration across human cancers

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

A census of human cancer genes

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

EGF-ERBB signalling: towards the systems level

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Improving treatment of HER2-positive cancers: opportunities and challenges

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation.

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Combinatorial drug therapy for cancer in the post-genomic era.

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Creating and analyzing pathway and protein interaction compendia for modelling signal transduction networks

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Systems biology and combination therapy in the quest for clinical efficacy.

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Merging systems biology with pharmacodynamics

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Training signaling pathway maps to biochemical data with constrained fuzzy logic: quantitative analysis of liver cell responses to inflammatory stimuli

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Logic-based models for the analysis of cell signaling networks

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

PI3K-dependent cross-talk interactions converge with Ras as quantifiable inputs integrated by Erk

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set.

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Dynamic interaction networks in a hierarchically organized tissue

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Systematic identification of genomic markers of drug sensitivity in cancer cells

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Identifying drug effects via pathway alterations using an integer linear programming optimization formulation on phosphoproteomic data

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Computational approaches for analyzing information flow in biological networks

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Intratumor heterogeneity: seeing the wood for the trees.

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Strategies for optimizing combinations of molecularly targeted anticancer agents

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Cancer genes and the pathways they control

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Cell-cell interaction networks regulate blood stem and progenitor cell fate

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Ultrasensitivity in the mitogen-activated protein kinase cascade

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Pharmacodynamic modeling of time-dependent transduction systems

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004008

21 January 2018

Identifiers

10.1126/SCISIGNAL.2004008

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23943608

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23943608

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47782406&oldid=2118878795"